MBX Biosciences Inc. (NASDAQ:MBX) is one of the stocks that will double in 2026. On December 4, Goldman Sachs initiated ...

CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

Phase 1 trial shows MBX 1416 is safe and well-tolerated, advancing to Phase 2 for PBH in late 2025. MBX Biosciences announced positive Phase 1 clinical trial results for its investigational drug MBX ...

MBX Biosciences, Inc. is rated a Buy, driven by canvuparatide's once-weekly dosing advantage in hypoparathyroidism. Learn ...

CARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

MBX Biosciences has filed to raise $100 million in an IPO to advance its clinical-stage programs for endocrine and metabolic disorder treatments, although the final figure may differ. The firm's lead ...

Goldman Sachs initiated coverage of MBX Biosciences (MBX) with a Sell rating and $18 price target The key issue for MBX over the next year will be ...

Visit a quote page and your recently viewed tickers will be displayed here. Patrick J. Heron was the founder of QuatRx Pharmaceuticals Co. (founded in 2000) and held the title of Director from 2012 to ...

(RTTNews) - MBX Biosciences, Inc. (MBX), announced Monday that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for MBX 4291, its long-acting GLP-1/GIP ...

On Tuesday, MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in healthy adult volunteers. MBX 1416 is the company ...

Visit a quote page and your recently viewed tickers will be displayed here. Tiba Aynechi is currently the Director at Avalyn Pharma, Inc., the Independent Director at Spruce Biosciences, Inc., the ...